Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by 2019champson Feb 03, 2021 8:28pm

148 Views

Post# 32466594

Anyone see cassava sciences?

This company was trading at $3 in late 2020 and as i write this its trading at $120 after hours as a result of phase 2 success. The company is targeting the alzheimers market. Totally different market, but why am i writing this? This is why alot of us are invested in arch and the science. Overnight with some good data we could be trading in the double digits. Now do i think this is going to $100 overnight after phase 2? Probably not. But with some positive data and a decent percentage of efficacy i can really see this take off.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver